1 citations
,
January 2004 in “Linchuang pifuke zazhi” Topical cyclosporin-A is recommended for severe alopecia areata.
44 citations
,
January 2021 in “Research” MCSA hydrogels can effectively treat melanoma and aid wound healing.
4 citations
,
September 2022 in “Journal of The American Academy of Dermatology” Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
April 2024 in “Skin health and disease” Using a special skin cream with gabapentin helped reduce symptoms of a certain scalp condition but didn't change nerve fibers or skin chemicals.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology” November 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.
2 citations
,
August 2011 in “Cochrane Database of Systematic Reviews”
January 2025 in “Acta Dermatovenerologica Alpina Pannonica et Adriatica” Baricitinib is effective and safe for treating severe alopecia areata.
October 2022 in “CRC Press eBooks” Cinchona pubescens is a medicinal plant from the Andes with potential health benefits, but more research is needed to fully understand it.
18 citations
,
January 2013 in “Evidence-based Complementary and Alternative Medicine” Aconiti Lateralis Preparata Radix helps mouse stem cells grow and turn into bone cells faster than usual methods.
38 citations
,
November 2005 in “Epilepsia” Levetiracetam is widely used and generally well-tolerated for treating idiopathic generalized epilepsies, with tiredness as the main side effect.
44 citations
,
October 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in Korean patients.
44 citations
,
August 1996 in “Drugs & Aging” Mitoxantrone is effective for treating acute leukemia, especially in older patients, with a lower risk of heart damage.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
May 2026 in “Journal of Neurosciences in Rural Practice” Tofacitinib may cause nerve damage in the brain, so monitor for neurological symptoms.
January 2026 in “Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna)” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
59 citations
,
January 2010 in “Pharmacognosy Reviews/Bioinformatics Trends/Pharmacognosy review” Semecarpus anacardium Linn. has many medicinal benefits.
9 citations
,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
September 2024 in “Journal of the American Academy of Dermatology” Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.
83 citations
,
May 2021 in “Biomolecules” The 5/G hydrogel effectively improves diabetic wound healing.
October 2025 in “Dermatology and Therapy” Ritlecitinib is being tested for effectiveness and safety in treating severe alopecia areata.
26 citations
,
July 2012 in “Endocrine Connections” Mitotane changes steroid breakdown, affecting cortisol availability.
4 citations
,
October 2000 in “Contraception” The right dosage of CPA and TB can work as a safe and reversible male contraceptive in monkeys.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
5 citations
,
July 2024 in “Journal of Market Access & Health Policy” Insurance coverage for scalp cooling will make it more accessible to all chemotherapy patients.
78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
1 citations
,
December 2012 in “Journal of dermatological science” Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.